Combining in vivo and in vitro studies to elucidate the inhibitory effect of resveratrol on vorolanib metabolism
Runjuan Zhan
IntroductionVorolanib is a new-generation multi-targeted kinase inhibitor (MTKI) whose drug-drug interaction (DDI) profile remains largely unexplored. This study combined in vitro and in vivo approaches to systematically investigate the effect of resveratrol on vorolanib metabolism.MethodsUsing ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), the concentrations of vorolanib and its primary active metabolite X297 were quantified in rat liver microsomes (RLM), human l